Search

Your search keyword '"Azais, Isabelle"' showing total 28 results
Start Over Author "Azais, Isabelle"
28 results on '"Azais, Isabelle"'

1. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

Author

Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V., Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M., Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves–Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J., Lipkin, Steven M., McKay, James D., and Dumontet, Charles

Published
2019
Full Text
View/download PDF

7. Profile of Long-Term Survivors in Multiple Myeloma

Author

Sabirou, Florence, primary, Defossez, Gautier, additional, Ingrand, Pierre, additional, Azais, Isabelle, additional, Durand, Geraldine, additional, Moya, Niels, additional, Gruchet, Cécile, additional, Levy, Anthony, additional, Bobin, Arthur, additional, Gardeney, Helene, additional, Nsiala, Laly, additional, Motard, Carine, additional, Olivier, Gaelle, additional, Corby, Anne, additional, Roul, Christophe, additional, Systchenko, Thomas, additional, Barrier, Jocelyn, additional, Dieval, Celine, additional, Borde, Florence, additional, Fitoussi, Olivier, additional, Machet, Antoine, additional, Jamet, Pierre, additional, Diolez, Jeremie, additional, Guidez, Stephanie, additional, Leleu, Xavier, additional, and Puyade, Mathieu, additional

Published
2019
Full Text
View/download PDF

8. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V, Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M, Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves-Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J, Lipkin, Steven M, McKay, James D, Dumontet, Charles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V, Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M, Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves-Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J, Lipkin, Steven M, McKay, James D, and Dumontet, Charles

Abstract

To the Editor, Multiple myeloma (MM) is the third most common hematological malignancy, after Non-Hodgkin Lymphoma and Leukemia. MM is generally preceded by Monoclonal Gammopathy of Undetermined Significance (MGUS) [1], and epidemiological studies have identified older age, male gender, family history, and MGUS as risk factors for developing MM [...]

Published
2019

9. Weekly 20/56mg/m2 Carfilzomib, Lenalidomide and Dexamethasone until progression in Early Relapsed Refractory Multiple Myeloma

Author

GRUCHET, Cecile, primary, Richez, Valentine, additional, Guidez, Stephanie, additional, Sabirou, Florence, additional, Moya, Niels, additional, Levy, Anthony, additional, Bobin, Arthur, additional, Gardeney, Helene, additional, Nsiala, Laly, additional, Machet, Antoine, additional, FOUQUET, Guillemette, additional, Azais, Isabelle, additional, Durand, Geraldine, additional, Avet-Loiseau, Herve, additional, and Leleu, Xavier, additional

Published
2019
Full Text
View/download PDF

10. Pomalidomide 3rd line versus 4th line for in Early Relapsed Refractory Multiple Myeloma

Author

GRUCHET, Cecile, primary, Guidez, Stephanie, additional, Tomowiak, Cecile, additional, Sabirou, Florence, additional, Moya, Niels, additional, Levy, Anthony, additional, Bobin, Arthur, additional, Gardeney, Helene, additional, Nsiala, Laly, additional, Machet, Antoine, additional, Azais, Isabelle, additional, Durand, Geraldine, additional, Richez, Valentine, additional, FOUQUET, Guillemette, additional, Avet-Loiseau, Herve, additional, and Leleu, Xavier, additional

Published
2019
Full Text
View/download PDF

11. Weekly 20/56 mg/m² carfilzomib, lenalidomide, and dexamethasone until progression in early relapsed refractory multiple myeloma.

Author

Gruchet, Cecile, primary, Richez, Valentine, additional, Guidez, Stephanie, additional, Fouquet, Guillemette, additional, Azais, Isabelle, additional, Durand, Geraldine, additional, Javaugue, Vincent, additional, Plasse, Florent, additional, Machet, Antoine, additional, Moya, Niels, additional, Gardeney, Helene, additional, Bobin, Arthur, additional, Levy, Anthony, additional, Sabirou, Florence, additional, Bonnin, Anthony, additional, Dieval, Celine, additional, Primault, Sylvain, additional, Bridoux, Frank, additional, Avet-Loiseau, Herve, additional, and Leleu, Xavier, additional

Published
2019
Full Text
View/download PDF

12. Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma

Author

Richez, Valentine, primary, Gruchet, Cécile, additional, Guidez, Stephanie, additional, Fouquet, Guillemette, additional, Azais, Isabelle, additional, Durand, Geraldine, additional, Javaugue, Vincent, additional, Brigaud, Antoine, additional, Plasse, Florent, additional, Diolez, Jeremie, additional, Machet, Antoine, additional, Moya, Niels, additional, Gardeney, Helene, additional, Franques, Paul, additional, Bobin, Arthur, additional, Levy, Anthony, additional, Sabirou, Florence, additional, Bonnin, Anthony, additional, Dieval, Celine, additional, Primault, Sylvain, additional, Barrier, Jocelyn, additional, Fleck, Emmanuel, additional, Bouyier, Sabrina, additional, Daras, Claire, additional, Princet, Isabelle, additional, Bauwens, Delphine, additional, Legros, Laurence, additional, Fuzibet, Jean-Gabriel, additional, Gil, Angela, additional, Bridoux, Franck, additional, Avet-Loiseau, Hervé, additional, and Leleu, Xavier, additional

Published
2018
Full Text
View/download PDF

13. Chronic HCV Infection and Autologous Stem Cell Transplantation for Multiple Myeloma

Author

Gruchet, Cécile, primary, Guidez, Stephanie, additional, Fouquet, Guillemette, additional, Azais, Isabelle, additional, Durand, Geraldine, additional, Javaugue, Vincent, additional, Brigaud, Antoine, additional, Plasse, Florent, additional, Diolez, Jeremie, additional, Sabirou, Florence, additional, Moya, Niels, additional, Bobin, Arthur, additional, Systchenko, Thomas, additional, Machet, Antoine, additional, Desmier, Deborah, additional, Levy, Anthony, additional, Dieval, Celine, additional, Primault, Sylvain, additional, Barrier, Jocelyn, additional, Corby, Anne, additional, Daras, Claire, additional, Princet, Isabelle, additional, Bauwens, Delphine, additional, Richez, Valentine, additional, Franques, Paul, additional, Gardeney, Helene, additional, Bouyer, Sabrina, additional, Dindinaud, Elodie, additional, Avet Loiseau, Herve, additional, Bridoux, Franck, additional, Christine, Silvain, additional, and Leleu, Xavier, additional

Published
2018
Full Text
View/download PDF

14. Carfilzomib weekly 20/56 mg/m2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma

Author

Richez, Valentine, primary, Gruchet, Cecile, additional, Guidez, Stephanie, additional, Fouquet, Guillemette, additional, Azais, Isabelle, additional, Durand, Geraldine, additional, Javaugue, Vincent, additional, Brigaud, Antoine, additional, Plasse, Florent, additional, Diolez, Jéremie, additional, Machet, Antoine, additional, Moya, Niels, additional, Gardeney, Helene, additional, Franques, Paul, additional, Bobin, Arthur, additional, Levy, Anthony, additional, Sabirou, Florence, additional, Bonnin, Anthony, additional, Dieval, Celine, additional, Primault, Sylvain, additional, Barrier, Jocelyn, additional, Fleck, Emmanuel, additional, Bouyier, Sabrina, additional, Daras, Claire, additional, Princet, Isabelle, additional, Bauwens, Delphine, additional, Legros, Laurence, additional, Fuzibet, Jean-Gabriel, additional, Gil, Angela, additional, Bridoux, Frank, additional, Avet-Loiseau, Hervé, additional, and Leleu, Xavier, additional

Published
2018
Full Text
View/download PDF

16. Rhumatologie (2° Éd.) (collection Le livre de l'interne)

Author

DEBIAIS Françoise, AZAÏS Isabelle, BONTOUX Daniel, DEBIAIS Françoise, AZAÏS Isabelle, and BONTOUX Daniel

Subjects
Rheumatology--Handbooks, manuals, etc
Abstract

Discipline transversale, la rhumatologie a profondément et rapidement évolué ces dernières années, comme en témoignent les nouvelles thérapeutiques ayant vu le jour et les progrès de l'imagerie. Cette nouvelle édition entièrement actualisée et augmentée rassemble de façon concise l'ensemble des éléments et des informations indispensables aux internes et aux spécialistes :• les méthodes d'exploration disponibles sont analysées une à une ;• les diagnostics et conduites pratiques expliquent en détail comment aborder, détecter et résoudre toutes les situations cliniques auxquelles l'interne peut être confronté ;• les pathologies de l'appareil locomoteur sont étudiées dans leur ensemble, de la polyarthrite rhumatoïde à l'arthrose en passant par l'ostéoporose, les vascularites, les connectivites, etc. ;• enfin, les thérapeutiques sont présentées par classes en tenant compte des dernières nouveautés dans la spécialité.Réunissant une soixantaine de spécialistes de renom, cette deuxième édition, agrémentée de nombreuses illustrations et d'un index détaillé, est un guide indispensable pour tous les internes en rhumatologie, mais également pour les professionnels qui pourront vérifier et remettre à jour leurs connaissances.

Published
2014

17. Carfilzomib weekly 20/56 mg/m2, lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.

Author

Richez, Valentine, Gruchet, Cecile, Guidez, Stephanie, Fouquet, Guillemette, Azais, Isabelle, Durand, Geraldine, Javaugue, Vincent, Brigaud, Antoine, Plasse, Florent, Diolez, Jéremie, Machet, Antoine, Moya, Niels, Gardeney, Helene, Franques, Paul, Bobin, Arthur, Levy, Anthony, Sabirou, Florence, Bonnin, Anthony, Dieval, Celine, and Primault, Sylvain

Published
2019
Full Text
View/download PDF

18. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Hulin, Cyrille, Belch, Andrew, Shustik, Chaim, Petrucci, Maria Teresa, Dührsen, Ulrich, Lu, Jin, Song, Kevin, Rodon, Philippe, Pégourié, Brigitte, Garderet, Laurent, Hunter, Hannah, Azais, Isabelle, Eek, Richard, Gisslinger, Heinz, Macro, Margaret, Dakhil, Shaker, Goncalves, Cristina, LeBlanc, Richard, Romeril, Ken, Royer, Bruno, Doyen, Chantal, Leleu, Xavier, Offner, Fritz, Leupin, Nicolas, Houck, Vanessa, Chen, Guang, Ervin-Haynes, Annette, Dimopoulos, Meletios A, Facon, Thierry, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Hulin, Cyrille, Belch, Andrew, Shustik, Chaim, Petrucci, Maria Teresa, Dührsen, Ulrich, Lu, Jin, Song, Kevin, Rodon, Philippe, Pégourié, Brigitte, Garderet, Laurent, Hunter, Hannah, Azais, Isabelle, Eek, Richard, Gisslinger, Heinz, Macro, Margaret, Dakhil, Shaker, Goncalves, Cristina, LeBlanc, Richard, Romeril, Ken, Royer, Bruno, Doyen, Chantal, Leleu, Xavier, Offner, Fritz, Leupin, Nicolas, Houck, Vanessa, Chen, Guang, Ervin-Haynes, Annette, Dimopoulos, Meletios A, and Facon, Thierry

Abstract

Purpose This analysis of the FIRST trial in patients with newly diagnosed multiple myeloma (MM) ineligible for stem-cell transplantation examined updated outcomes and impact of patient age. Patients and Methods Patients with untreated symptomatic MM were randomly assigned at a one-to-one-to-one ratio to lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks), stratified by age (≤ 75 v > 75 years), disease stage (International Staging System stage I/II v III), and country. The primary end point was progression-free survival. Rd continuous and MPT were primary comparators. Results Between August 21, 2008, and March 7, 2011, 1,623 patients were enrolled (Rd continuous, n = 535; Rd18, n = 541; MPT, n = 547), including 567 (35%) age older than 75 years. Higher rates of advanced-stage disease and renal impairment were observed in patients older than 75 versus 75 years of age or younger. Rd continuous reduced the risk of progression or death compared with MPT by 31% (hazard ratio [HR], 0.69; 95% CI, 0.59 to 0.80; P < .001) overall, 36% (HR, 0.64; 95% CI, 0.53 to 0.77; P < .001) in patients age 75 years or younger, and 20% (HR, 0.80; 95% CI, 0.62 to 1.03; P = .084) in those age older than 75 years. Median overall survival was longer with Rd continuous than with MPT, including a 14-month difference in patients age older than 75 years. Progression-free survival with Rd18 was similar to that with MPT, and overall survival with Rd18 was marginally inferior to that with Rd continuous. Rates of grade 3 to 4 treatment-emergent adverse events were similar for Rd continuous-treated patients age 75 years or older and those age older than 75 years; however, older patients had more frequent lenalidomide dose reductions. Conclusion Results support Rd continuous treatment as a new standard of care for stem-cell transplantation-ineligible patients with newly diagnosed M

Published
2016

19. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

Author

Hulin, Cyrille, primary, Belch, Andrew, additional, Shustik, Chaim, additional, Petrucci, Maria Teresa, additional, Dührsen, Ulrich, additional, Lu, Jin, additional, Song, Kevin, additional, Rodon, Philippe, additional, Pégourié, Brigitte, additional, Garderet, Laurent, additional, Hunter, Hannah, additional, Azais, Isabelle, additional, Eek, Richard, additional, Gisslinger, Heinz, additional, Macro, Margaret, additional, Dakhil, Shaker, additional, Goncalves, Cristina, additional, LeBlanc, Richard, additional, Romeril, Ken, additional, Royer, Bruno, additional, Doyen, Chantal, additional, Leleu, Xavier, additional, Offner, Fritz, additional, Leupin, Nicolas, additional, Houck, Vanessa, additional, Chen, Guang, additional, Ervin-Haynes, Annette, additional, Dimopoulos, Meletios A., additional, and Facon, Thierry, additional

Published
2016
Full Text
View/download PDF

20. Exome sequencing identifies germline variants in DIS3in familial multiple myeloma

Author

Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V., Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M., Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves–Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J., Lipkin, Steven M., McKay, James D., and Dumontet, Charles

Published
2019
Full Text
View/download PDF

21. Carfilzomib Weekly 20/56mg/m², Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma

Author

Valentine, Richez, Guidez, Stephanie, Azais, Isabelle, Durand, Geraldine, Javaugue, Vincent, Brigaud, Antoine, Plasse, Florent, Diolez, Jeremie, Machet, Antoine, Moya, Niels, Gruchet, Cécile, Bobin, Arthur, Levy, Anthony, Sabirou, Florence, Bonnin, Anthony, Dieval, Celine, Primault, Sylvain, Barrier, Jocelyn, Fleck, Emmanuel, Daras, Claire, Princet, Isabelle, Bauwens, Delphine, Fouquet, Guillemette, Bridoux, Frank, Avet Loiseau, Herve, and Leleu, Xavier

Published
2017
Full Text
View/download PDF

22. Prognostic Significance of Plasmablastic Plasma Cells in the Era of Novel Agents in Multiple Myeloma

Author

Machet, Antoine, Guidez, Stephanie, Fouquet, Guillemette, Systchenko, Thomas, Desmier, Deborah, Moya, Niels, Gruchet, Cécile, Levy, Anthony, Sabirou, Florence, Bobin, Arthur, Richez, Valentine, Dieval, Celine, Motard, Carine, Borde, Florence, Durand, Geraldine, Azais, Isabelle, Javaugue, Vincent, Tomowiak, Cecile, Bouyer, Sabrina, Ghoual, Ouda, Dindinaud, Elodie, Bridoux, Frank, Sonneveld, Pieter, avet Loiseau, Herve, and Leleu, Xavier

Published
2017
Full Text
View/download PDF

23. Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone (Rd): The First Trial

Author

Hulin, Cyrille, primary, Facon, Thierry, additional, Shustik, Chaim, additional, Belch, Andrew, additional, Petrucci, Maria Teresa, additional, Dührsen, Ulrich, additional, Lu, Jin, additional, Song, Kevin, additional, Rodon, Philippe, additional, Pegourie, Brigitte, additional, Garderet, Laurent, additional, Hunter, Hannah, additional, Azais, Isabelle, additional, Eek, Richard, additional, Macro, Margaret, additional, Dakhil, Shaker, additional, Houck, Vanessa, additional, Chen, Guang, additional, Ervin-Haynes, Annette, additional, and Offner, Fritz, additional

Published
2014
Full Text
View/download PDF

24. Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial

Author

UCL - MD/MINT - Département de médecine interne, Hulin, Cyrille, Facon, Thierry, Rodon, Philippe, Pegourie, Brigitte, Benboubker, Lotfi, Doyen, Chantal, Dib, Mamoun, Guillerm, Gaelle, Salles, Bruno, Eschard, Jean-Paul, Lenain, Pascal, Casassus, Philippe, Azais, Isabelle, Decaux, Olivier, Garderet, Laurent, Mathiot, Claire, Fontan, Jean, Lafon, Ingrid, Virion, Jean Marc, Moreau, Philippe, 49th Annual Meeting of the American-Society-of-Hematology, UCL - MD/MINT - Département de médecine interne, Hulin, Cyrille, Facon, Thierry, Rodon, Philippe, Pegourie, Brigitte, Benboubker, Lotfi, Doyen, Chantal, Dib, Mamoun, Guillerm, Gaelle, Salles, Bruno, Eschard, Jean-Paul, Lenain, Pascal, Casassus, Philippe, Azais, Isabelle, Decaux, Olivier, Garderet, Laurent, Mathiot, Claire, Fontan, Jean, Lafon, Ingrid, Virion, Jean Marc, Moreau, Philippe, and 49th Annual Meeting of the American-Society-of-Hematology

Abstract

Purpose Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma. The addition of thalidomide to this combination demonstrated a survival benefit for patients age 65 to 75 years. This randomized, placebo-controlled, phase III trial investigated the efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed myeloma. Patients and Methods Between April 2002 and December 2006, 232 previously untreated patients with myeloma, age 75 years or older, were enrolled and 229 were randomly assigned to treatment. All patients received melphalan (0.2 mg/kg/d) plus prednisone (2 mg/kg/d) for 12 courses (day 1 to 4) every 6 weeks. Patients were randomly assigned to receive 100 mg/d of oral thalidomide (n = 113) or placebo (n = 116), continuously for 72 weeks. The primary end point was overall survival. Results After a median follow-up of 47.5 months, overall survival was significantly longer in patients who received melphalan and prednisone plus thalidomide compared with those who received melphalan and prednisone plus placebo (median, 44.0 v 29.1 months; P = .028). Progression-free survival was significantly prolonged in the melphalan and prednisone plus thalidomide group (median, 24.1 v 18.5 months; P = .001). Two adverse events were significantly increased in the melphalan and prednisone plus thalidomide group: grade 2 to 4 peripheral neuropathy (20% v 5% in the melphalan and prednisone plus placebo group; P < .001) and grade 3 to 4 neutropenia (23% v 9%; P = .003). Conclusion This trial confirms the superiority of the combination melphalan and prednisone plus thalidomide over melphalan and prednisone alone for prolonging survival in very elderly patients with newly diagnosed myeloma. Toxicity was acceptable. J Clin Oncol 27: 3664-3670. (C) 2009 by American Society of Clinical Oncology

Published
2009

25. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome

Author

Avet-Loiseau, Hervé, primary, Attal, Michel, additional, Moreau, Philippe, additional, Charbonnel, Catherine, additional, Garban, Frédéric, additional, Hulin, Cyrille, additional, Leyvraz, Serge, additional, Michallet, Mauricette, additional, Yakoub-Agha, Ibrahim, additional, Garderet, Laurent, additional, Marit, Gérald, additional, Michaux, Lucienne, additional, Voillat, Laurent, additional, Renaud, Marc, additional, Grosbois, Bernard, additional, Guillerm, Gaelle, additional, Benboubker, Lotfi, additional, Monconduit, Mathieu, additional, Thieblemont, Catherine, additional, Casassus, Philippe, additional, Caillot, Denis, additional, Stoppa, Anne-Marie, additional, Sotto, Jean-Jacques, additional, Wetterwald, Marc, additional, Dumontet, Charles, additional, Fuzibet, Jean-Gabriel, additional, Azais, Isabelle, additional, Dorvaux, Véronique, additional, Zandecki, Marc, additional, Bataille, Régis, additional, Minvielle, Stéphane, additional, Harousseau, Jean-Luc, additional, Facon, Thierry, additional, and Mathiot, Claire, additional

Published
2007
Full Text
View/download PDF

27. Pomalidomide 3rd Line Versus 4thLine for RRMM

Author

Gruchet, Cécile, Guidez, Stephanie, Fouquet, Guillemette, Durand, Geraldine, Azais, Isabelle, Javaugue, Vincent, Brigaud, Antoine, Diolez, Jeremie, Plasse, Florent, Sabirou, Florence, Bobin, Arthur, Moya, Niels, Machet, Antoine, Systchenko, Thomas, Desmier, Deborah, Levy, Anthony, Dieval, Celine, Primault, Sylvain, Barrier, Jocelyn, Corby, Anne, Borde, Florence, Daras, Claire, Princet, Isabelle, Bauwens, Delphine, Richez, Valentine, Bridoux, Franck, Avet-Loiseau, Hervé, and Leleu, Xavier

Abstract

Background.Pomalidomide in association with dexamethasone is approved for RRMM in 3rdline and beyond based on the multicenter international phase 3MM-003 study that demonstrated greater efficacy for Pomalidomide plus dexamethasone over high dose dexamethasone. However, MM-003 mainly recruited RRMM with 5 prior lines +, and very few data are available regarding real life Pomalidomide-based treatment in 3rdand 4thline RRMM.

Published
2017
Full Text
View/download PDF

28. Carfilzomib weekly 20/56 mg/m 2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.

Author

Richez V, Gruchet C, Guidez S, Fouquet G, Azais I, Durand G, Javaugue V, Brigaud A, Plasse F, Diolez J, Machet A, Moya N, Gardeney H, Franques P, Bobin A, Levy A, Sabirou F, Bonnin A, Dieval C, Primault S, Barrier J, Fleck E, Bouyier S, Daras C, Princet I, Bauwens D, Legros L, Fuzibet JG, Gil A, Bridoux F, Avet-Loiseau H, and Leleu X

Subjects
Aged, Aged, 80 and over, Dexamethasone administration & dosage, Drug Administration Schedule, Female, Humans, Kaplan-Meier Estimate, Lenalidomide administration & dosage, Male, Middle Aged, Oligopeptides administration & dosage, Progression-Free Survival, Recurrence, Salvage Therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Multiple Myeloma drug therapy
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results